AED | Audio Epilepsy Digest podcast

Episode 17: What Counts as Neuromodulation Success?

0:00
47:05
Reculer de 15 secondes
Avancer de 15 secondes

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 17: What Counts as Neuromodulation Success?

Should the 50% responder rate remain the primary definition of neuromodulation success?

This episode stages the strongest case for a simple common benchmark against the strongest case for a multidimensional clinical verdict. VNS, pediatric thalamic DBS and RNS, long-term RNS, ESTEL, CONNECTiVOS, PuLsE, and two biomarker studies are used to test what the threshold captures—and what it hides.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-017-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- Keep the 50% responder rate as a standardized anchor, but never let it stand alone.
- Pair any threshold with the underlying reduction distribution, seizure freedom, denominator, and time horizon.
- Similar 12-month responder proportions do not prove similar early experience or device superiority.
- Quality of life, harms, and treatment burden are core counseling domains rather than decorative secondary outcomes.
- ESTEL preserved a negative diary primary comparison alongside a positive secondary ambulatory-EEG responder signal; objective detection and patient importance are not synonyms.
- A high AUC in a tiny held-out split or a post-treatment blood-marker association is hypothesis-generating, not a patient-selection tool.

Papers discussed:
- Zhao et al. Vagus nerve stimulation as an add-on therapy in patients with epilepsy. Acta Epileptologica. 2026. doi:10.1186/s42494-026-00272-4.
- Tenhoeve et al. Comparative multicenter evaluation of thalamic neuromodulation for treatment-resistant epilepsy in children. Epilepsia. 2026. doi:10.1002/epi.70402.
- Zhou et al. Nonlinear neurodynamics of N2 sleep EEG predict outcomes of ANT-DBS in epilepsy. Journal of Neural Engineering. 2026. doi:10.1088/1741-2552/ae94b2.
- Tang et al. Peripheral blood inflammatory biomarkers and response to VNS in pediatric drug-resistant epilepsy. European Journal of Pediatrics. 2026. doi:10.1007/s00431-026-07256-z.
- Niazi et al. What defines response to VNS in children with drug-resistant epilepsy? Epilepsia. 2025. doi:10.1111/epi.18520.
- Dalic et al. DBS of Thalamic Centromedian Nucleus for Lennox-Gastaut Syndrome (ESTEL Trial). Annals of Neurology. 2022. doi:10.1002/ana.26280.
- Nair et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology. 2020. doi:10.1212/WNL.0000000000010154.
- Ryvlin et al. The long-term effect of VNS on quality of life: The PuLsE trial. Epilepsia. 2014. doi:10.1111/epi.12611.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-017-ai-review.html

Editorial disclosure:
Two independent AI-assisted reviews cleared the final candidate with minor notes and no blocking source-fidelity or clinical-safety finding. The first draft was withheld after it confused an electrographic responder proportion with seizure-reduction magnitude and described interval seizure freedom as cure. The corrected final draft preserves endpoint hierarchy, denominators, design limits, and the research-stage status of proposed biomarkers. The clinician-editor authorized shipment for Monday at 7:00 AM EDT.

D'autres épisodes de "AED | Audio Epilepsy Digest"